Antibacterial properties of the CFTR potentiator ivacaftor

Background Ivacaftor increases CFTR channel activity and improves pulmonary function for individuals bearing a G551D mutation. Because ivacaftor structurally resembles quinolone antibiotics, we tested the hypothesis that ivacaftor possesses antibacterial properties. Methods Bioluminescence, colony forming unit, and minimal inhibitory concentration assays were … Continued

Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis

BACKGROUND: Chronic rhinosinusitis is common in cystic fibrosis (CF), as CFTR defects equally affect the airway and sinonasal mucosa. However, therapeutic strategies for CF-associated chronic rhinosinusitis lag behind current approaches for pulmonary disease. OBJECTIVE: To assess the tolerability and efficacy … Continued

CURx Pharmaceuticals Announces License Agreement with Gilead Sciences

CURx Pharmaceuticals today announced it has entered into a global license agreement with Gilead Sciences, Inc. for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for Phase III clinical trials, having successfully completed … Continued

AIT Expands NOxCureCF Phase II Clinical Trial for Cystic Fibrosis

Advanced Inhalation Therapies (AIT Ltd.), a drug development company, announced today it added Schneider Children’s Medical Center of Israel as the second site in its multicenter, open-label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis. Schneider Children’s is the largest children’s … Continued

CF Trust partners with NovaBiotics Ltd and Health Sciences Scotland for development of Lynovex

Lynovex®, a recognised treatment for a non CF-related condition, is being developed as a treatment for persistent lung infection in cystic fibrosis, thanks to a partnership between the Cystic Fibrosis Trust, Health Sciences Scotland and biotech company NovaBiotics Ltd. The … Continued